State Board of Administration of Florida Retirement System Purchases New Position in Viridian Therapeutics, Inc. (NASDAQ:VRDN)

State Board of Administration of Florida Retirement System purchased a new stake in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDNGet Rating) during the second quarter, HoldingsChannel.com reports. The firm purchased 11,040 shares of the company’s stock, valued at approximately $128,000.

A number of other hedge funds also recently bought and sold shares of VRDN. Royal Bank of Canada purchased a new position in Viridian Therapeutics during the 1st quarter valued at about $128,000. Gyon Technologies Capital Management LP purchased a new position in Viridian Therapeutics during the 1st quarter valued at about $225,000. PDT Partners LLC increased its holdings in Viridian Therapeutics by 14.1% during the 1st quarter. PDT Partners LLC now owns 14,390 shares of the company’s stock valued at $266,000 after purchasing an additional 1,775 shares during the period. Bank of America Corp DE increased its holdings in Viridian Therapeutics by 87.4% during the 1st quarter. Bank of America Corp DE now owns 17,833 shares of the company’s stock valued at $330,000 after purchasing an additional 8,319 shares during the period. Finally, JPMorgan Chase & Co. increased its holdings in Viridian Therapeutics by 43.2% during the 1st quarter. JPMorgan Chase & Co. now owns 18,666 shares of the company’s stock valued at $345,000 after purchasing an additional 5,633 shares during the period.

Viridian Therapeutics Stock Performance

Shares of VRDN opened at $23.09 on Wednesday. The company has a quick ratio of 17.35, a current ratio of 17.35 and a debt-to-equity ratio of 0.02. The business’s 50 day moving average price is $20.51 and its 200-day moving average price is $16.76. Viridian Therapeutics, Inc. has a 52 week low of $9.47 and a 52 week high of $26.22. The stock has a market cap of $657.23 million, a P/E ratio of -5.46 and a beta of 0.84.

Insider Transactions at Viridian Therapeutics

In other news, General Counsel Lara Meisner sold 8,125 shares of the business’s stock in a transaction that occurred on Tuesday, November 15th. The stock was sold at an average price of $22.05, for a total value of $179,156.25. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 4.48% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts recently issued reports on the company. LADENBURG THALM/SH SH boosted their price target on Viridian Therapeutics from $33.00 to $40.00 and gave the company a “buy” rating in a report on Tuesday, August 16th. Wedbush upped their target price on Viridian Therapeutics to $43.00 in a report on Thursday, November 17th. B. Riley upped their target price on Viridian Therapeutics from $25.00 to $40.00 in a report on Tuesday, August 16th. SVB Leerink upped their target price on Viridian Therapeutics from $32.00 to $40.00 and gave the stock an “outperform” rating in a report on Monday, August 15th. Finally, Evercore ISI upped their target price on Viridian Therapeutics from $40.00 to $50.00 in a report on Monday, August 15th.

Viridian Therapeutics Company Profile

(Get Rating)

Viridian Therapeutics, Inc, a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-003, a therapeutic antibody targeting IGF-1R for the treatment of TED.

Recommended Stories

Want to see what other hedge funds are holding VRDN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Viridian Therapeutics, Inc. (NASDAQ:VRDNGet Rating).

Institutional Ownership by Quarter for Viridian Therapeutics (NASDAQ:VRDN)

Receive News & Ratings for Viridian Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viridian Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.